Advocacy intelligence hub — real-time data for patient organizations
Medicines Development for Global Health — PHASE3
National Institute of Allergy and Infectious Diseases (NIAID)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
OTEZLA�
Amgen Inc.
Enbrel
(etanercept)Orphan drugstandardImmunex Corporation
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important rol...
OTEZLA�
(apremilast)Orphan drugstandardAmgen Inc.
Phosphodiesterase 4 Inhibitor [EPC]
12.1 Mechanism of Action Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAM...
Remicade
(infliximab)Orphan drugstandardJanssen Biotech, Inc.
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms o...
Peter U Fischer, PhD
Washington University School of Medicine
Christopher L King, MD PhD
Case Western Reserve University
Gary J Weil, MD, M.D
Washington University School of Medicine
📍 BELLEVUE, WA
Nicholas O Opoku, MD
University of Health and Allied Sciences School of Public Health, Hohoe, Ghana
Eric Ottesen, MD, M.D
Neglected Tropical Disease Support Center
📍 WASHINGTON, DC
Michel Mandro, MD
Chef de Bureau Inspection&Contrôle et Associé de Recherche Clinique